

March 15, 2014 • Volume 20 • Number 6

Table of Contents

Table of Contents

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

CORRECTION

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a section of an intracranial glioblastoma (GBM); GBM cells express the fluorescent protein citrine (green) and the High-mobility group protein B1 (HMGB1) fused to the red fluorescent protein cherry. In living cells HMGB1 is located in the nucleus; upon cell death, HMGB1 is translocated to the cytoplasm and is eventually secreted. Circulating levels of HMGB1 may constitute a noninvasive surrogate biomarker of therapeutic efficacy. For details, see the article by Candolfi and colleagues on page 1555 of this issue.



Clinical Cancer Research

20 (6)

Clin Cancer Res 2014;20:1399-1706.